Eli Lilly (LLY) Current Deferred Tax Assets (2009 - 2010)
Eli Lilly (LLY) posted Current Deferred Tax Assets of $297.8 million for Q3 2010, down 5.28% quarter-over-quarter from $314.4 million in Q2 2010, and up 12.93% year-on-year from $263.7 million in Q3 2009.
Eli Lilly (LLY) Current Deferred Tax Assets (2009 - 2010) Analysis & Trends
Eli Lilly (LLY) has reported Current Deferred Tax Assets for 2 consecutive years, with $297.8 million the latest figure, recorded in Q3 2010.
- Current Deferred Tax Assets for Q3 2010 came in at $297.8 million, up 12.93% year-over-year; the trailing twelve-month figure through Sep 2010 was $297.8 million (up 12.93% YoY), and the FY2009 annual result was $271.0 million, changed N/A from the prior year.
- Current Deferred Tax Assets was $297.8 million for Q3 2010 at Eli Lilly, down from $314.4 million in the prior quarter.
- Over five years, Current Deferred Tax Assets peaked at $314.4 million in Q2 2010 and troughed at $263.7 million in Q3 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2010 | 297.80 Mn |
| Sep 30, 2010 | 297.80 Mn |
| Jun 30, 2010 | 314.40 Mn |
| Jun 30, 2010 | 314.40 Mn |
| Mar 31, 2010 | 275.20 Mn |
| Mar 31, 2010 | 275.20 Mn |
| Dec 31, 2009 | 271.00 Mn |
| Dec 31, 2009 | 271.00 Mn |
| Sep 30, 2009 | 263.70 Mn |
| Sep 30, 2009 | 263.70 Mn |
| Jun 30, 2009 | 290.60 Mn |
| Jun 30, 2009 | 290.60 Mn |